Summit outlines November 14 FDA PDUFA date for ivonescimab BLA while planning HARMONi-3 PFS in 2H 2026

BLA FilingivonescimabNeutral

AI Analysis

Summary

Summit Therapeutics announced a November 14, 2026 FDA PDUFA decision date for ivonescimab BLA while planning to present HARMONi-3 Phase 3 progression-free survival data in the second half of 2026.

Clinical Trial Data

Phase

Importance:8/10

Sentiment:

0.00

FDA_PDUFABLAivonescimabPhase_3HARMONi-3

Related Companies

$SMMT

Read the original article

Published by Seeking Alpha Healthcare on July 24, 2026 2:41 AM

Read Original